Vicapsys Life Sciences, Inc. Share Price

Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.